PCN491 PATIENT REPORTED OUTCOMES (PRO) OF TALAZOPARIB (TALA) VERSUS PHYSICIAN'S CHOICE OF CHEMOTHERAPY (PCT) IN PATIENTS (PTS) WITH ADVANCED BREAST CANCER (ABC) AND A GERMLINE BRCA (GBRCA) MUTATION: A FOCUS ON EMBRACA PTS WITH/ WITHOUT PRIO ...
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.683
https://www.valueinhealthjournal.com/article/S1098-3015(19)33061-X/fulltext
Title :
PCN491 PATIENT REPORTED OUTCOMES (PRO) OF TALAZOPARIB (TALA) VERSUS PHYSICIAN'S CHOICE OF CHEMOTHERAPY (PCT) IN PATIENTS (PTS) WITH ADVANCED BREAST CANCER (ABC) AND A GERMLINE BRCA (GBRCA) MUTATION: A FOCUS ON EMBRACA PTS WITH/ WITHOUT PRIO ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)33061-X&doi=10.1016/j.jval.2019.09.683
First page :
Section Title :
Open access? :
No
Section Order :
10595